期刊
PRIMARY CARE RESPIRATORY JOURNAL
卷 20, 期 1, 页码 15-22出版社
PRIMARY CARE RESPIRATORY SOC-PCRS UK
DOI: 10.4104/pcrj.2010.00060
关键词
COPD; early diagnosis; early treatment; primary care
资金
- UK National Health Service
- Aerocrine
- AstraZeneca
- Boehringer Ingelheim
- GlaxoSmithKline
- Merck
- Sharpe
- Dohme
- Novartis
- Pfizer
- Schering Plough
- Teva
- Nycomed
Chronic obstructive pulmonary disease (COPD) is a progressive disease that begins many years before a diagnosis is usually made. The need for an early and confirmed diagnosis of COPD is increasingly appreciated by primary care physicians in whose hands the ability to make improvements in early diagnosis largely rests. Case-finding of patients with symptoms of lifestyle limitation is probably the most practical way to achieve early diagnosis. Evidence suggests a burden of early COPD on afflicted people and their families. Early encouragement of smoking cessation, in conjunction with management of symptoms and treating activity limitation and exacerbations by appropriate non-pharmacologic and pharmacologic management at the earliest possible stage, could positively affect the impact and progression of the disease. (C) 2011 Primary Care Respiratory Society UK. All rights reserved. Q Zhang et al. Prim Care Respir J 2011; 20(1): 97-101 doi:10.4104/pcrj.2010.00061
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据